Extrahepatic portal venous obstruction (EHPO)
is an important cause of upper gastrointestinal bleeding in our centre, constituting 46% of all the patients with portal hypertension presenting as a variceal bleed. ' In approximately half of the patients, portosystemic shunt surgery is not possible, either because there is a complete block of the splenoportal axis or the diameter of the splenic vein is too small for shunt surgery. Moreover, shunt surgery has its own mortality and morbidity associated with thrombosis of the shunt, postoperative infection, and uncommonly portosystemic encephalopathy.2-7 Endoscopic sclerotherapy has become increasingly popular for the treatment of oesophageal varices, both in arresting active bleeding and preventing recurrent bleeding.8 '24 Most of these studies, however, have been in patients with cirrhosis. This study was planned to assess the effect of sclerotherapy on variceal bleeding/obliteration and patient morbidity/mortality in extra hepatic portal venous obstruction.
Methods

PATIENTS
One hundred and twenty two patients (102 men and 20 women), age range from 1½2 to 55 years (mean age 17-2 (6 4)) with portal hypertension caused by EHPO and recurrent variceal bleeding were entered into the sclerotherapy programme from September 1983 to June 1988 (Table I) . No patient had any stigmata of chronic liver disease. All patients had obstruction of the splenoportal venous system as seen on splenoportovenography. Liver function tests were normal in all patients, except three who had a reversed albumin-globulin ratio. Liver biopsy was performed in these three patients to exclude chronic liver disease.
All the patients had bled from oesophageal varices at presentation. Bleeding stopped spontaneously in 92 (75 4%) patients, while it was controlled with the Sengstaken-Blakemore tube in 30 (24 6%) patients before sclerotherapy. The varices were graded from I-IV as described by Paquet'3 and all the patients treated had grade III-IV varices. Sclerotherapy was performed using a flexible forward viewing endoscope (Olympus GIF-Q) and an indigenously designed needle. 25 Premedication was given with pentazocine and hyoscine butylbromide (Buscopan) iv to achieve anaglesia and aperistalsis. General anaesthesia was only given to children if they were uncooperative or below six years of age. Oesophageal varices were injected intravariceally (as far as possible) in a circumferential manner near the gastroesophageal junction and 2-3 cm proximally. The sclerosant used was 3% sodium tetradecyl sulphate (STD). Usually 1-2 ml sclerosant was injected at each site, not exceeding a total of 10 ml per session. The patients received nil by mouth for four hours after the procedure. Endoscopic sclerotherapy was repeated at three-week intervals until the varices were obliterated and this was considered as the end point of the treatment. Variceal obliteration was achieved when there was non-visualisation (Table II) The 95 patients in whom varices were obliterated were followed up for a mean period of 23-69 (Table IV) Three patients had successful surgery (two a side-to-side lienorenal shunt, and one an oesophagogastric devascularisation). Surgery was chosen because these patients could not afford to travel long distances each time to receive sclerotherapy. MORTALITY (Table IV) Six (5 77%) patients died of bleeding -five before having been obliterated, and one 12 months after obliteration, probably from a bleeding gastric varix. All died at home for want of timely medical attention and of the five who died before variceal obliteration, three died after six sessions, one after three sessions, and one after two sessions of sclerotherapy.
RESULTS ACCORDING TO AGE (Table IV) The patients were arbitrarily divided into 'adults' when they were above 15 29 It is therefore important that in order to reduce the morbidity and mortality associated with frequent variceal bleeds and repeated blood transfusions management of this condition must be aimed at prevention of recurrent variceal haemorrhage. This could either be achieved by decompressing the portal venous system by surgical shunts, or through obliteration of the submucosal oesophageal varices by sclerotherapy.
The results of surgical decompression need to be evaluated with respect to the operative mortality, rebleeding rate and encephalpathy2-' and compared with the results of sclerotherapy.
Two large series available from India23 one of them from our own centre,3 deal with the results of shunt surgery in extrahepatic portal venous obstruction. The operative mortality in these two series was 2 2% and 10 1% respectively.23
The rebleeding rates (which would logically approximate the incidence of blocked shunts) were 15% and 21-4% respectively and encephalopathy consequent to portal diversion occurred in none of the patients in the two series. These results would seem to indicate that surgery has a definite role to play in the management of patients with EHPO. A cumulative analysis of shunt surgery in EHPO, however (which also included one of the above mentioned series from India) quoted the overall mortality and rebleeding rate to be 4-7% and 45-3% respectively.4
An alternative therapy -that is, sclerotherapy -has been subjected to much critical analysis in patients with portal hypertension caused by cirrhosis.8'-A number of studies are available evaluating the effect of sclerotherapy in patients with EHPO'2-14 but in most of these the numbers ofpatients were small (range 4-16 patients) and a large proportion had already undergone earlier surgery for portal hypertension. Moreover Endoscopic sclerotherapy is therefore, an effective and safe therapy for patients with extrahepatic portal venous obstruction. A comparison with the results of surgery in the two large series available from India studying similar groups of patients show that the bleeding rate after variceal obliteration is actually less than the rebleeding rate after shunt surgery. Moreover, a large proportion (54%) of patients with EHPO either have a complete splenoportal block or a splenic vein that is small in diameter and hence non-shuntable (unpublished observations). Finally, the longterm effects of portal diversion in such patients are not yet known. There are reports to suggest that operated patients with EHPO may develop encephalopathy despite good liver function.26 3 These advantages, in addition to the fact that the complication rates observed are not very different from the surgical series, make endoscopic sclerotherapy the procedure of choice in such patients. We do, however, acknowledge that sclerotherapy has a disadvantage in terms of time and frequent trips to the hospital in order to complete the course of treatment.
In conclusion, it is felt that endoscopic sclerosis of oesophageal varices is an effective treatment for patients with EHPO, achieving results comparable with those of shunt surgery, with the advantage it can be done in the outpatient department. The final opinion, however, can only be given after sclerotherapy and shunt surgery are compared in a prospective randomised trial with a longterm follow up. One such trial has been undertaken in our centre and the results of which will be available in the near future.
